|Researchers at Purdue University have developed a technology to assess the cellular effects of potential drugs designed as agonists of cell surface proteins known as G protein-coupled receptors (GPCRs). GPCR agonists carry out their therapeutic effect by controlling GPCR-mediated signaling. Agonist binding can result in recruitment of beta arrestin proteins to the GPCR. Whether the drug preferentially recruits beta-arrestin 1 or beta-arrestin 2 will influence the drug’s therapeutic and adverse effects. Traditional setups that assess beta-arrestin recruitment require two separate assays. The Purdue system empowers researchers to quickly identify agonists that are biased toward recruitment of the desired beta-arrestin isoform by monitoring both isoforms over time in a single cell. The Purdue technology uses protein complementation, with a fragment of a luminescent protein fused to the GPCR and different complementary fragments fused to each arrestin isoform. The assay yields green, red, or a combination of green and red luminescence depending on how the GPCR recruits beta-arrestins in the presence of an agonist. The researchers have successfully demonstrated the concept with the GPCR, delta opioid receptor, and obtained dose-response curves with two delta opioid receptor agonists. The approach demonstrated with the delta opioid receptor will also be useful for screening other GPCR drug targets.
-Single assay for simultaneously assessing recruitment of two beta-arrestin isoforms
-Kinetic tracking of beta-arrestin recruitment in real-time
-Rapid discovery of beta-arrestin isoform biased agonists
-Drug Discovery and Development
Technology Validation: Obtained dose-response curves with two delta opioid receptor agonists.
Apr 2, 2021
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486